{"title":"StemRegenin 1 selectively promotes expansion of Multipotent Hematopoietic Progenitors derived from Human Embryonic Stem Cells.","authors":"Lihong Tao, Padma Priya Togarrati, Kyung-Dal Choi, Kran Suknuntha","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Human embryonic stem cell (hESC)-derived hematopoietic stem/progenitor cells hold tremendous potential as alternative cell sources for the treatment of various hematological diseases, drug discovery and toxicological screening. However, limited number of hematopoietic stem/progenitor cells generated from the differentiation of hESCs hinders their downstream applications. Here, we show that aryl hydrocarbon receptor antagonist StemRegenin 1 (SR1) selectively promotes expansion of hESC-derived lin<sup>-</sup>CD34<sup>+</sup> hematopoietic progenitors in a concentration-dependent manner. The colony-forming cell (CFC) activity was found to be enriched in the CD34<sup>+</sup> cells that were expanded with SR1; however, these cells have less colony-forming activity as compared to unexpanded cells (1,338 vs. 7 of CD34<sup>+</sup> cells to form 1 colony, respectively). Interestingly, SR1 showed a bipotential effect on the proliferation of CD34 negative population, that is low dose of SR1 (1 µM) enhanced cell proliferation, whereas it was repressed at higher doses (>5 µM). In summary, our results suggest that SR1 has the potential to facilitate expansion of hESC-derived lin<sup>-</sup>CD34<sup>+</sup> hematopoietic progenitors, which further retain the potential to form multilineage hematopoietic colonies.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2017-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786649/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stem Cells & Regenerative Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
Abstract
Human embryonic stem cell (hESC)-derived hematopoietic stem/progenitor cells hold tremendous potential as alternative cell sources for the treatment of various hematological diseases, drug discovery and toxicological screening. However, limited number of hematopoietic stem/progenitor cells generated from the differentiation of hESCs hinders their downstream applications. Here, we show that aryl hydrocarbon receptor antagonist StemRegenin 1 (SR1) selectively promotes expansion of hESC-derived lin-CD34+ hematopoietic progenitors in a concentration-dependent manner. The colony-forming cell (CFC) activity was found to be enriched in the CD34+ cells that were expanded with SR1; however, these cells have less colony-forming activity as compared to unexpanded cells (1,338 vs. 7 of CD34+ cells to form 1 colony, respectively). Interestingly, SR1 showed a bipotential effect on the proliferation of CD34 negative population, that is low dose of SR1 (1 µM) enhanced cell proliferation, whereas it was repressed at higher doses (>5 µM). In summary, our results suggest that SR1 has the potential to facilitate expansion of hESC-derived lin-CD34+ hematopoietic progenitors, which further retain the potential to form multilineage hematopoietic colonies.
人类胚胎干细胞(hESC)衍生的造血干细胞/祖细胞在治疗各种血液疾病、药物发现和毒理学筛选方面具有巨大的替代细胞来源潜力。然而,hESCs分化产生的造血干细胞/祖细胞数量有限,阻碍了其下游应用。在这里,我们发现芳基烃受体拮抗剂StemRegenin 1 (SR1)以浓度依赖的方式选择性地促进hesc来源的lin-CD34+造血祖细胞的扩增。在SR1扩增的CD34+细胞中发现集落形成细胞(CFC)活性增强;然而,与未扩增的细胞相比,这些细胞的集落形成活性较低(CD34+细胞形成1个集落的数量分别为1,338 vs 7)。有趣的是,SR1对CD34阴性群体的增殖表现出双电位效应,即低剂量SR1(1µM)促进细胞增殖,而高剂量SR1(>5µM)则抑制细胞增殖。总之,我们的研究结果表明SR1具有促进hesc衍生的lin-CD34+造血祖细胞扩增的潜力,这些祖细胞进一步保留了形成多系造血集落的潜力。